Answers are grounded in this paper and cite their sources.
Demonstrates enhanced electrochemiluminescence detection of α-synuclein, indicating a promising method for early Parkinson’s screening.
Precise quantification of α-synuclein (α-Syn), an important species associated with Parkinson’s disease and related neurodegenerative disorders, is of paramount importance for early diagnosis and intervention. While electrochemiluminescence (ECL) has emerged as a powerful analytical technique owing to its low background interference and high sensitivity, the performance of MOF-based ECL systems is often limited by sluggish interfacial charge transfer and insufficient co-reactant activation at a single type of catalytic site. To overcome these bottlenecks, a two-dimensional (2D) ZnCu metal-organic framework/TiO 2 (ZCMT) heterojunction sensing system was constructed by coupling interface engineering with a dual-site synergistic catalysis strategy. Specifically, the heterojunction facilitates directional charge transport by promoting electron delocalization and interfacial charge redistribution. Concurrently, the Cu- and Ti-based redox-active centers synergistically facilitate K 2 S 2 O 8 activation and accelerate its reduction. This synergistic mechanism substantially enhances its ECL performance. By integrating the ZCMT platform with DNAzyme-assisted amplification strategy, a high-performance ECL biosensor was constructed for the ultrasensitive quantification of α-Syn. Overall, this study provides an effective strategy for overcoming the charge-transfer and catalytic limitations of MOF-based ECL systems and establishes a promising platform for the ultrasensitive analysis of α-Syn, with potential applications in the early screeningof Parkinson’s disease.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: